Followers | 375 |
Posts | 16969 |
Boards Moderated | 4 |
Alias Born | 03/07/2014 |
Thursday, April 03, 2014 6:13:21 PM
Why start over, waste money/resources of which you have very little (5 employees, maybe a a few $hundred thous cash at any given time, total R&D last yr of about $600K which is what, about $50K a month per last 10-K) on going back to phase I, when you have a phase III called Mirror and a phase II/III called Marvel, Marvel now being about 4 plus yrs old and gone nowhere? All for essentially the same product line, key product? Doesn't make sense IMO?
It's a long, long ways from a phase I, to get to a phase III and beyond. Baxter is doing a phase III, stem-cell-heart related trial right now, listed on clinicaltrials.gov, and it began in 2012 and shows an "expected" end date, just for final data of 2016. That's 4 yrs in my book. That's just the phase III portion. There was probably 1 to 2 yrs more for the initial phase I ,then phase II to get to that phase III. So that's about 6 or 7 yrs total.
Why post old news about Angel? It's been posted many times before already? Curious/interesting IMO?
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM